The allure of high-tech cardiac imaging has proved strong enough to entice venture capitalists to invest $21 million in NexRay, developers of a low-dose x-ray fluoroscopy system. The fledgling product, which uses a proprietary technology called
The allure of high-tech cardiac imaging has proved strong enough to entice venture capitalists to invest $21 million in NexRay, developers of a low-dose x-ray fluoroscopy system. The fledgling product, which uses a proprietary technology called Scanning-Beam Digital X-ray, promises to deliver 3-D imaging applicable to the interventional cardiology market. NexRay, formerly Cardiac Mariners, promises improved image quality and up to 90% reduction in radiation exposure to the patient and staff.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.